Dr. Chinnaiyan is the S.P. Hicks Professor of Pathology and Urology and Director of the Michigan Center for Translational Pathology. He is also an Investigator for the Howard Hughes Medical Institute and a member of the Institute of Medicine of the National Academy of Sciences. His laboratory is focused on cancer genomics and bioinformatics and is likely best known for the 2005 discovery of recurrent gene fusions in common solid tumors (specifically TMPRSS2-ETS gene fusions in prostate cancer), seminal work on EZH2, and development of the Oncomine cancer database. Dr. Chinnaiyan co-founded Compendia Biosciences (2006-present) to focus on cancer bioinformatics and Armune Biosciences (2007-present) to develop immune biomarkers of cancer. Compendia Biosciences was UM start-up company that received support from SPARK and the Michigan Development Corporation (MEDC) and has grown to become a profitable company with more than 34 employees and  established partnerships with 15 of the top 20 oncology biopharma. In October of 2012, Compendia had a successful exit for investors and was acquired by Life Technologies for further expansion and development in the State of Michigan. Dr. Chinnaiyan, through the University, has also licensed cancer diagnostics technology to Gen-Probe, Inc. and Ventana/Roche. He serves as an SAB member or consultant to Gen-Probe, Inc., Ventana/Roche, Compendia Biosciences/Life Technologies, Molecular MD, Wafergen, and Metabolon. Dr. Chinnaiyan has over 280 publications and 8 patents. Dr. Chinnaiyan will serve as Chair of the Scientific Advisory Board and Co-Founder of OncoFusion.

 Pathology and Urology